SURVYR

AKBLF

ALK-Abelló A/S
$36.50
+$0.00 (0.00%)Oct 26 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-7%+3%+12%+22%+32%Oct 2025Oct 2026Apr 202652w high $40.6552w low $30.50
AKBLFSPY
Wall St. Highest PT $51.58 (+41.3%) Wall St. Avg PT $42.28 (+15.8%)
$30$36$42$47$53POC $34Hi $52Avg $42
Underwater Drawdown %Max DD -25.0%Current -10.2%
0.0%-25.0%
Relative Strength vs SPY+5.8% vs SPYOutperforming
+29%0%-29%
1W
+$2.80 (8.31%)
1M
+$6.00 (19.67%)
3M
−$1.42 (3.73%)
6M
+$0.95 (2.66%)
YTD
+$2.20 (6.40%)
1Y
+$5.76 (18.73%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street & Morningstar coverage
Wall Street consensusNo covering analysts on file for AKBLF
Analyst price targetsNo target range on file
Morningstar star ratingNot rated
Checked Wall Street & Morningstar feeds · All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$7.5B
P/E (last 12 months)35.5
P/E (next 12 months, estimated)42.1
52-week range$30.50 – $40.65
Revenue growth (latest quarter vs a year ago)+17.6%
Dividend yield0.73%

What they do

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

No SEC filings found for this ticker (foreign filer, ETF or fund).

For information only · Important disclosures

Grades vs sector

No sector grades for AKBLF yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

AKBLF earningsNext report in 20 days
Next report
Tue Nov 17, 2026Time not confirmed
EPS consensus$1.70
Revenue consensus–
Source: Yahoo Finance · refreshed 2026-10-26 18:38:52 ET
No EPS history available.

News & catalysts

More news
No recent headlines.

Stats refreshed 2026-10-26 18:38:52 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026